Keywords: Pfizer, Financia results, Third-quarter 2012, EU negative, Taliglucerase alfa, Gaucher disease, Protalix

Pfizer 3rd-qtr profits slump on lower than expected sales; EU says "no" to Gaucher drug

Article | 02 November 2012

Print This

US pharma behemoth Pfizer (NYSE: PFE) saw it shares fall 1.1% to $24.59 in morning trading yesterday, when the company reported financial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in